<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01052480</url>
  </required_header>
  <id_info>
    <org_study_id>10-I-0043</org_study_id>
    <secondary_id>IRC002</secondary_id>
    <nct_id>NCT01052480</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza</brief_title>
  <acronym>IRC002</acronym>
  <official_title>A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, open-label, multicenter phase 2 trial will assess the safety, efficacy, and
      pharmacokinetics (PK) of anti-influenza plasma in subjects with influenza A or B.
      Hospitalized subjects with influenza A or B that have either a low oxygen level or a high
      respiratory rate will be eligible for study participation. This study will enroll adults,
      children and pregnant women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Morbidity and mortality occur despite treatment with current antivirals. Circulating
      influenza H1N1 and H3N2 isolates are highly resistant to amantadine and rimantadine, whereas
      previous seasonal H1N1 isolates were highly resistant to oseltamivir. So there is concern
      that circulating influenza A/H1N1 2009 virus may also acquire oseltamivir resistance.

      This randomized, open-label, multicenter phase 2 trial will assess the safety, efficacy, and
      pharmacokinetics (PK) of anti-influenza plasma in subjects with influenza. Hospitalized
      subjects with influenza at risk for severe disease (as defined in the inclusion criteria)
      will be eligible for study participation. This study will enroll adults, children and
      pregnant women.

      Up to 40 sites in the United States will participate in this protocol. One hundred eligible
      subjects will be randomized in a 1:1 ratio to receive either 2 units (or pediatric
      equivalent) of anti-influenza immune plasma on Study Day 0 in addition to standard care or
      standard care alone (50 subjects receiving standard care alone; 50 subjects receiving
      anti-influenza immune plasma and standard care).

      Subjects will be assessed on Study Day 0 (pre-dose), 30 minutes post-dose (plasma arm only),
      and on Study Days 1, 2, 4, 7, 14, and 28. All subjects will undergo a series of efficacy,
      safety, and PK (HAI) assessments during the study. Blood samples will be collected at each
      time point (except Day 1). Nasal and oropharyngeal swabs for influenza PCR will be obtained
      on Days 0,1,2,4 and 7.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2010</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Normalization of Respiratory Status (Primary Efficacy Population)</measure>
    <time_frame>Measured from Day 0 through Day 28</time_frame>
    <description>Normalized respiratory status is defined as room air saturation of oxygen [SaO2] greater than or equal to 93% AND respiratory rate within normal ranges.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Normalization of Respiratory Status (All Randomized Participants)</measure>
    <time_frame>Measured from Day 0 through Day 28</time_frame>
    <description>Normalized respiratory status is defined as room air saturation of oxygen [SaO2] greater than or equal to 93% AND respiratory rate within normal ranges.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Time to Resolution of Clinical Symptoms</measure>
    <time_frame>Measured from Day 0 through Day 28</time_frame>
    <description>The assessed clinical symptoms were nausea, vomiting, diarrhea, sore throat, headache, muscle ache, cough, and shortness of breath. Symptoms were assessed at days 0, 1, 2, 4, 7, 14, and 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Time to Resolution of Fever</measure>
    <time_frame>Measured from Day 0 through Day 28</time_frame>
    <description>Fever was defined as either a temperature &gt; 38.0 C, or a report of a Grade 1 or higher fever as an adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Time to Resolution of All Symptoms and Fever</measure>
    <time_frame>Measured from Day 0 through Day 28</time_frame>
    <description>The assessed symptoms were nausea, vomiting, diarrhea, sore throat, headache, muscle ache, cough, and shortness of breath. Fever was defined as either a temperature &gt; 38.0 C, or a report of a Grade 1 or higher fever as an adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 20% Improvement in Sequential Organ Failure Assessment (SOFA) Score for Participants &gt;= 18 Years Old and Pediatric Logistic Organ Dysfunction (PELOD) Score for Participants &lt; 18 Years Old</measure>
    <time_frame>Measured from Day 0 through Day 28</time_frame>
    <description>The analysis is restricted to participants &gt;= 18 years old and the SOFA score because there were very few evaluations of the PELOD score during follow-up for the participants &lt; 18 years old. The adult population was further subset to those with a non-missing and non-zero SOFA score at Day 0; those with missing SOFA score at Day 0 did not have a starting point, and those with SOFA = 0 at Day 0 could not have an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>50 Millimeters of Mercury (mm/Hg) Improvement in PaO2/FiO2 Ratio Over Time</measure>
    <time_frame>Measured at Days 1, 2, 4, 7, 14, 28</time_frame>
    <description>Number of participants with ABG done and no increase of 50 millimeters of mercury (mm/Hg) or greater in PaO2/FiO2 ratio. PaO2/FiO2 ratio was evaluated by an ABG. ABG was performed only when clinically indicated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital Mortality</measure>
    <time_frame>Measured from Day 0 through Day 28</time_frame>
    <description>Number of deaths in hospital during initial hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day Mortality</measure>
    <time_frame>Measured from Day 0 through Day 28</time_frame>
    <description>Number of deaths during study follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Hospitalization</measure>
    <time_frame>Measured from Day 0 through Day 28</time_frame>
    <description>Days that a participant spent at the hospital. Multiple hospitalizations are summed up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ICU Admissions</measure>
    <time_frame>Measured from Day 0 through Day 28</time_frame>
    <description>Number of ICU admissions during study follow-up. The intent was to analyze any number of ICU admissions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Stay in ICU</measure>
    <time_frame>Measured from Day 0 through Day 28</time_frame>
    <description>Days that a participant spent in ICU. Multiple ICU admissions are summed up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days on Supplemental Oxygen</measure>
    <time_frame>Measured from Day 0 through Day 28</time_frame>
    <description>Time (in days) of supplemental oxygen use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Supplemental Oxygen</measure>
    <time_frame>Measured from Day 0 through Day 28</time_frame>
    <description>Duration of supplemental oxygen use in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Acute Respiratory Distress Syndrome (ARDS) Present</measure>
    <time_frame>Measured at Days 0, 1, 2, 4, 7, 14, 28</time_frame>
    <description>Incidence of participants with acute respiratory distress syndrome (ARDS), restricted to those without ARDS at Day 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days on Mechanical Ventilation</measure>
    <time_frame>Measured from Day 0 through Day 28</time_frame>
    <description>Time (in days) of mechanical ventilation use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Mechanical Ventilation</measure>
    <time_frame>Measured from Day 0 through Day 28</time_frame>
    <description>Duration of mechanical ventilation use in days. Multiple mechanical ventilation durations are summed up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disposition Following Initial Hospitalization</measure>
    <time_frame>Measured from Day 0 through Day 28</time_frame>
    <description>Disposition following initial hospitalization was categorized as follows: &quot;released home - home health care not required&quot;, &quot; released home with home health care&quot;, &quot;transferred to long-term care facility&quot;, &quot;hospitalization ongoing at Day 28&quot;, &quot;deceased&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Viral Shedding &lt; Lower Limit of Quantification (LLOQ) in Nasal Swabs</measure>
    <time_frame>Measured from Day 0 through Day 28</time_frame>
    <description>Duration of viral shedding &lt; lower limit of quantification (LLOQ) in nasal swabs (restricted to participants with viral shedding &gt;= LLOQ in nasal swabs at Day 0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Week of Gestation of Delivery of a Live Pre-term Infant for Pregnant Women</measure>
    <time_frame>Measured through to Day 28</time_frame>
    <description>Incidence and week of gestation of delivery of a live pre-term infant for pregnant female participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Duration of Pre-term Labor (Defined as Labor Occurring &lt; 36 Weeks) for Pregnant Women</measure>
    <time_frame>Measured through Day 28</time_frame>
    <description>Incidence and duration of pre-term labor (defined as labor occurring &lt; 36 weeks) for pregnant female participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Spontaneous Abortion or Stillborn Fetus for Pregnant Women</measure>
    <time_frame>Measured from Day 0 through Day 28</time_frame>
    <description>Incidence of spontaneous abortion or stillborn fetus for pregnant female participants</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Influenza A</condition>
  <condition>Influenza B</condition>
  <arm_group>
    <arm_group_label>Plasma and Standard Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies (Anti-Influenza Immune Plasma) in addition to standard care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive standard care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-Influenza Immune Plasma</intervention_name>
    <description>2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline</description>
    <arm_group_label>Plasma and Standard Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Care</intervention_name>
    <description>All subjects will receive an anti-influenza antiviral (e.g., oseltamivir or zanamivir), but may include treatment with licensed antivirals in patient populations or at doses not covered in the package insert, or with medications available under a EUA. Standard care may also include antibiotics and other medications.</description>
    <arm_group_label>Plasma and Standard Care</arm_group_label>
    <arm_group_label>Standard Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of influenza A or B within 72 hours prior to enrollment (by local assay
             including rapid antigen, direct fluorescent antibody (DFA), polymerase chain reaction
             (PCR), or culture, and must be able to detect and distinguish influenza A from
             influenza B)

          -  Hospitalization for signs and symptoms of influenza (decision for hospitalization will
             be up to the individual treating clinician).

          -  Abnormal respiratory status, defined as room air saturation of oxygen (SaO2) less than
             93% or tachypnea (respiratory rate above an age adjusted normal range)

          -  Agree to the storage of specimens and data

          -  ABO compatible plasma available on site or available within 24 hours after
             randomization with activity against locally circulating strains of influenza

        Exclusion Criteria:

          -  Receipt of non-licensed treatment for influenza within the last 2 weeks (or plans to
             receive any time during the study). This does not include licensed drugs at non
             approved doses, off-label indications, or drugs available under an Emergency Use
             Authorization (EUA).

          -  History of severe allergic reaction to blood products (as judged by the investigator).

          -  Medical conditions for which receipt of 500 mL volume (or 8 mL/kg for pediatric
             patients) may be dangerous to the subject (e.g. decompensated congestive heart failure
             [CHF], etc.)

          -  Clinical suspicion that etiology of acute illness is primarily due to a condition
             other than active influenza virus replication (e.g., a bacterial or fungal infection)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Beigel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Leidos Biomedical Research, Inc. in support of Laboratory of Immunoregulation, NIAID, NIH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Davey, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Laboratory of Immunoregulation, NIAID, NIH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naval Medical Center San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Los Angeles Biomedical Research Institute, CA</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington, DC VA Med Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University (NU)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine Center for Vaccine Development</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins University (JHU)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center (WRNMMC)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital/Harvard Medical School</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Med Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronson Healthcare Group</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Mary's Hospital (Mayo Clinic)</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell Clinical Trials Unit, New York Presbyterian Hospital, Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center/Albert Einstein College of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati College of Medicine</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center (UPMC)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Science Center (HSC)- Amarillo</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Tech HSC-Lubbock, TX</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79430</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naval Medical Center Portsmouth</name>
      <address>
        <city>Portsmouth</city>
        <state>Virginia</state>
        <zip>23708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madigan Army Medical Center (MAMC)</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/detail/B_2010-I-0043.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Morse SS. Factors in the emergence of infectious diseases. Emerg Infect Dis. 1995 Jan-Mar;1(1):7-15. Review.</citation>
    <PMID>8903148</PMID>
  </reference>
  <reference>
    <citation>Bean WJ, Schell M, Katz J, Kawaoka Y, Naeve C, Gorman O, Webster RG. Evolution of the H3 influenza virus hemagglutinin from human and nonhuman hosts. J Virol. 1992 Feb;66(2):1129-38.</citation>
    <PMID>1731092</PMID>
  </reference>
  <reference>
    <citation>de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, Nguyen VC, Bach VC, Phan TQ, Do QH, Guan Y, Peiris JS, Tran TH, Farrar J. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med. 2005 Dec 22;353(25):2667-72.</citation>
    <PMID>16371632</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2010</study_first_submitted>
  <study_first_submitted_qc>January 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2010</study_first_posted>
  <results_first_submitted>April 19, 2017</results_first_submitted>
  <results_first_submitted_qc>April 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 23, 2017</results_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antiviral</keyword>
  <keyword>Anti-Influenza Immune Plasma</keyword>
  <keyword>Emerging Infectious Disease</keyword>
  <keyword>Swine Flu</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Plasma and Standard Care</title>
          <description>Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies in addition to standard care.
Anti-Influenza Immune Plasma: 2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
Standard Care: Standard care for hospitalized people with influenza</description>
        </group>
        <group group_id="P2">
          <title>Standard Care</title>
          <description>Participants will receive standard care.
Standard Care: Standard care for hospitalized people with influenza</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Plasma and Standard Care</title>
          <description>Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies in addition to standard care.
Anti-Influenza Immune Plasma: 2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
Standard Care: Standard care for hospitalized people with influenza</description>
        </group>
        <group group_id="B2">
          <title>Standard Care</title>
          <description>Participants will receive standard care.
Standard Care: Standard care for hospitalized people with influenza</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="98"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" lower_limit="38" upper_limit="66"/>
                    <measurement group_id="B2" value="57" lower_limit="39" upper_limit="71"/>
                    <measurement group_id="B3" value="53" lower_limit="38" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <description>The &lt;18 and &gt;=18 categories match a protocol-specified division, so it is most appropriate to present categorized age this way.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Normalization of Respiratory Status (Primary Efficacy Population)</title>
        <description>Normalized respiratory status is defined as room air saturation of oxygen [SaO2] greater than or equal to 93% AND respiratory rate within normal ranges.</description>
        <time_frame>Measured from Day 0 through Day 28</time_frame>
        <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza.</population>
        <group_list>
          <group group_id="O1">
            <title>Plasma and Standard Care</title>
            <description>Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies in addition to standard care.
Anti-Influenza Immune Plasma: 2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Participants will receive standard care.
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Normalization of Respiratory Status (Primary Efficacy Population)</title>
          <description>Normalized respiratory status is defined as room air saturation of oxygen [SaO2] greater than or equal to 93% AND respiratory rate within normal ranges.</description>
          <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="2">Upper quartile is not available because fewer than 75% of the analyzed participants achieved normalized respiratory status. Lower quartile and median were estimated from Kaplan-Meier analysis.</measurement>
                    <measurement group_id="O2" value="28" lower_limit="7">Upper quartile is not available because fewer than 75% of the analyzed participants achieved normalized respiratory status. Lower quartile and median were estimated from Kaplan-Meier analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.069</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Normalization of Respiratory Status (All Randomized Participants)</title>
        <description>Normalized respiratory status is defined as room air saturation of oxygen [SaO2] greater than or equal to 93% AND respiratory rate within normal ranges.</description>
        <time_frame>Measured from Day 0 through Day 28</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Plasma and Standard Care</title>
            <description>Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies in addition to standard care.
Anti-Influenza Immune Plasma: 2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Participants will receive standard care.
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Normalization of Respiratory Status (All Randomized Participants)</title>
          <description>Normalized respiratory status is defined as room air saturation of oxygen [SaO2] greater than or equal to 93% AND respiratory rate within normal ranges.</description>
          <population>All randomized participants</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="2">Upper quartile is not available because fewer than 75% of the analyzed participants achieved normalized respiratory status. Lower quartile and median were estimated from Kaplan-Meier analysis.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="7">Median and upper quartile are not available because fewer than 50% of the analyzed participants achieved normalized respiratory status. Lower quartile was estimated from Kaplan-Meier analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Time to Resolution of Clinical Symptoms</title>
        <description>The assessed clinical symptoms were nausea, vomiting, diarrhea, sore throat, headache, muscle ache, cough, and shortness of breath. Symptoms were assessed at days 0, 1, 2, 4, 7, 14, and 28.</description>
        <time_frame>Measured from Day 0 through Day 28</time_frame>
        <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza.</population>
        <group_list>
          <group group_id="O1">
            <title>Plasma and Standard Care</title>
            <description>Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies in addition to standard care.
Anti-Influenza Immune Plasma: 2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Participants will receive standard care.
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Time to Resolution of Clinical Symptoms</title>
          <description>The assessed clinical symptoms were nausea, vomiting, diarrhea, sore throat, headache, muscle ache, cough, and shortness of breath. Symptoms were assessed at days 0, 1, 2, 4, 7, 14, and 28.</description>
          <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="14">Median and upper quartile are not available because fewer than 50% of the analyzed participants had symptoms resolved. Lower quartile was estimated from Kaplan-Meier analysis</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="28">Median and upper quartile are not available because fewer than 50% of the analyzed participants had symptoms resolved. Lower quartile was estimated from Kaplan-Meier analysis</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Time to Resolution of Fever</title>
        <description>Fever was defined as either a temperature &gt; 38.0 C, or a report of a Grade 1 or higher fever as an adverse event.</description>
        <time_frame>Measured from Day 0 through Day 28</time_frame>
        <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza.</population>
        <group_list>
          <group group_id="O1">
            <title>Plasma and Standard Care</title>
            <description>Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies in addition to standard care.
Anti-Influenza Immune Plasma: 2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Participants will receive standard care.
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Time to Resolution of Fever</title>
          <description>Fever was defined as either a temperature &gt; 38.0 C, or a report of a Grade 1 or higher fever as an adverse event.</description>
          <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="0">Median and upper quartile are not available because nearly all participants had no fever at Day 0. Lower quartile was estimated from Kaplan-Meier analysis.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="0">Median and upper quartile are not available because nearly all participants had no fever at Day 0. Lower quartile was estimated from Kaplan-Meier analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Time to Resolution of All Symptoms and Fever</title>
        <description>The assessed symptoms were nausea, vomiting, diarrhea, sore throat, headache, muscle ache, cough, and shortness of breath. Fever was defined as either a temperature &gt; 38.0 C, or a report of a Grade 1 or higher fever as an adverse event.</description>
        <time_frame>Measured from Day 0 through Day 28</time_frame>
        <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza.</population>
        <group_list>
          <group group_id="O1">
            <title>Plasma and Standard Care</title>
            <description>Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies in addition to standard care.
Anti-Influenza Immune Plasma: 2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Participants will receive standard care.
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Time to Resolution of All Symptoms and Fever</title>
          <description>The assessed symptoms were nausea, vomiting, diarrhea, sore throat, headache, muscle ache, cough, and shortness of breath. Fever was defined as either a temperature &gt; 38.0 C, or a report of a Grade 1 or higher fever as an adverse event.</description>
          <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="14">Median and upper quartile are not available because fewer than 50% of the analyzed participants had all symptoms and fever resolved. Lower quartile was estimated from Kaplan-Meier analysis.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="28">Median and upper quartile are not available because fewer than 50% of the analyzed participants had all symptoms and fever resolved. Lower quartile was estimated from Kaplan-Meier analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to 20% Improvement in Sequential Organ Failure Assessment (SOFA) Score for Participants &gt;= 18 Years Old and Pediatric Logistic Organ Dysfunction (PELOD) Score for Participants &lt; 18 Years Old</title>
        <description>The analysis is restricted to participants &gt;= 18 years old and the SOFA score because there were very few evaluations of the PELOD score during follow-up for the participants &lt; 18 years old. The adult population was further subset to those with a non-missing and non-zero SOFA score at Day 0; those with missing SOFA score at Day 0 did not have a starting point, and those with SOFA = 0 at Day 0 could not have an improvement.</description>
        <time_frame>Measured from Day 0 through Day 28</time_frame>
        <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza. This subset was further restricted to those &gt;= 18 years with an available (non-zero) Day 0 SOFA evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Plasma and Standard Care</title>
            <description>Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies in addition to standard care.
Anti-Influenza Immune Plasma: 2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Participants will receive standard care.
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
        </group_list>
        <measure>
          <title>Time to 20% Improvement in Sequential Organ Failure Assessment (SOFA) Score for Participants &gt;= 18 Years Old and Pediatric Logistic Organ Dysfunction (PELOD) Score for Participants &lt; 18 Years Old</title>
          <description>The analysis is restricted to participants &gt;= 18 years old and the SOFA score because there were very few evaluations of the PELOD score during follow-up for the participants &lt; 18 years old. The adult population was further subset to those with a non-missing and non-zero SOFA score at Day 0; those with missing SOFA score at Day 0 did not have a starting point, and those with SOFA = 0 at Day 0 could not have an improvement.</description>
          <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza. This subset was further restricted to those &gt;= 18 years with an available (non-zero) Day 0 SOFA evaluation.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2">Upper quartile is not available because fewer than 75% of the analyzed participants had 20% improvement in SOFA score. Median and lower quartile were estimated from Kaplan-Meier analysis.</measurement>
                    <measurement group_id="O2" value="28" lower_limit="7">Upper quartile is not available because fewer than 75% of the analyzed participants had 20% improvement in SOFA score. Median and lower quartile were estimated from Kaplan-Meier analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>50 Millimeters of Mercury (mm/Hg) Improvement in PaO2/FiO2 Ratio Over Time</title>
        <description>Number of participants with ABG done and no increase of 50 millimeters of mercury (mm/Hg) or greater in PaO2/FiO2 ratio. PaO2/FiO2 ratio was evaluated by an ABG. ABG was performed only when clinically indicated.</description>
        <time_frame>Measured at Days 1, 2, 4, 7, 14, 28</time_frame>
        <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza. This subset was further restricted to those participants with a PaO2/FiO2 ratio (ABG performed) at Day 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Plasma and Standard Care</title>
            <description>Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies in addition to standard care.
Anti-Influenza Immune Plasma: 2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Participants will receive standard care.
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
        </group_list>
        <measure>
          <title>50 Millimeters of Mercury (mm/Hg) Improvement in PaO2/FiO2 Ratio Over Time</title>
          <description>Number of participants with ABG done and no increase of 50 millimeters of mercury (mm/Hg) or greater in PaO2/FiO2 ratio. PaO2/FiO2 ratio was evaluated by an ABG. ABG was performed only when clinically indicated.</description>
          <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza. This subset was further restricted to those participants with a PaO2/FiO2 ratio (ABG performed) at Day 0.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-hospital Mortality</title>
        <description>Number of deaths in hospital during initial hospital admission</description>
        <time_frame>Measured from Day 0 through Day 28</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Plasma and Standard Care</title>
            <description>Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies in addition to standard care.
Anti-Influenza Immune Plasma: 2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Participants will receive standard care.
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
        </group_list>
        <measure>
          <title>In-hospital Mortality</title>
          <description>Number of deaths in hospital during initial hospital admission</description>
          <population>All randomized participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>28-day Mortality</title>
        <description>Number of deaths during study follow-up</description>
        <time_frame>Measured from Day 0 through Day 28</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Plasma and Standard Care</title>
            <description>Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies in addition to standard care.
Anti-Influenza Immune Plasma: 2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Participants will receive standard care.
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
        </group_list>
        <measure>
          <title>28-day Mortality</title>
          <description>Number of deaths during study follow-up</description>
          <population>All randomized participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Hospitalization</title>
        <description>Days that a participant spent at the hospital. Multiple hospitalizations are summed up.</description>
        <time_frame>Measured from Day 0 through Day 28</time_frame>
        <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza.</population>
        <group_list>
          <group group_id="O1">
            <title>Plasma and Standard Care</title>
            <description>Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies in addition to standard care.
Anti-Influenza Immune Plasma: 2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Participants will receive standard care.
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Hospitalization</title>
          <description>Days that a participant spent at the hospital. Multiple hospitalizations are summed up.</description>
          <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="4" upper_limit="16"/>
                    <measurement group_id="O2" value="11" lower_limit="5" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of ICU Admissions</title>
        <description>Number of ICU admissions during study follow-up. The intent was to analyze any number of ICU admissions.</description>
        <time_frame>Measured from Day 0 through Day 28</time_frame>
        <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza.</population>
        <group_list>
          <group group_id="O1">
            <title>Plasma and Standard Care</title>
            <description>Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies in addition to standard care.
Anti-Influenza Immune Plasma: 2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Participants will receive standard care.
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
        </group_list>
        <measure>
          <title>Number of ICU Admissions</title>
          <description>Number of ICU admissions during study follow-up. The intent was to analyze any number of ICU admissions.</description>
          <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 ICU admission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 ICU admissions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 ICU admissions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Stay in ICU</title>
        <description>Days that a participant spent in ICU. Multiple ICU admissions are summed up.</description>
        <time_frame>Measured from Day 0 through Day 28</time_frame>
        <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza.</population>
        <group_list>
          <group group_id="O1">
            <title>Plasma and Standard Care</title>
            <description>Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies in addition to standard care.
Anti-Influenza Immune Plasma: 2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Participants will receive standard care.
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Stay in ICU</title>
          <description>Days that a participant spent in ICU. Multiple ICU admissions are summed up.</description>
          <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days on Supplemental Oxygen</title>
        <description>Time (in days) of supplemental oxygen use</description>
        <time_frame>Measured from Day 0 through Day 28</time_frame>
        <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza.</population>
        <group_list>
          <group group_id="O1">
            <title>Plasma and Standard Care</title>
            <description>Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies in addition to standard care.
Anti-Influenza Immune Plasma: 2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Participants will receive standard care.
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
        </group_list>
        <measure>
          <title>Days on Supplemental Oxygen</title>
          <description>Time (in days) of supplemental oxygen use</description>
          <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="1" upper_limit="28"/>
                    <measurement group_id="O2" value="8" lower_limit="3" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Supplemental Oxygen</title>
        <description>Duration of supplemental oxygen use in days</description>
        <time_frame>Measured from Day 0 through Day 28</time_frame>
        <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza.</population>
        <group_list>
          <group group_id="O1">
            <title>Plasma and Standard Care</title>
            <description>Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies in addition to standard care.
Anti-Influenza Immune Plasma: 2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Participants will receive standard care.
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Supplemental Oxygen</title>
          <description>Duration of supplemental oxygen use in days</description>
          <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="1" upper_limit="28"/>
                    <measurement group_id="O2" value="8" lower_limit="3" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Acute Respiratory Distress Syndrome (ARDS) Present</title>
        <description>Incidence of participants with acute respiratory distress syndrome (ARDS), restricted to those without ARDS at Day 0.</description>
        <time_frame>Measured at Days 0, 1, 2, 4, 7, 14, 28</time_frame>
        <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza. This population is further restricted to those participants who did not have ARDS at Day 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Plasma and Standard Care</title>
            <description>Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies in addition to standard care.
Anti-Influenza Immune Plasma: 2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Participants will receive standard care.
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Acute Respiratory Distress Syndrome (ARDS) Present</title>
          <description>Incidence of participants with acute respiratory distress syndrome (ARDS), restricted to those without ARDS at Day 0.</description>
          <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza. This population is further restricted to those participants who did not have ARDS at Day 0.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days on Mechanical Ventilation</title>
        <description>Time (in days) of mechanical ventilation use</description>
        <time_frame>Measured from Day 0 through Day 28</time_frame>
        <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza.</population>
        <group_list>
          <group group_id="O1">
            <title>Plasma and Standard Care</title>
            <description>Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies in addition to standard care.
Anti-Influenza Immune Plasma: 2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Participants will receive standard care.
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
        </group_list>
        <measure>
          <title>Days on Mechanical Ventilation</title>
          <description>Time (in days) of mechanical ventilation use</description>
          <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="6"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Mechanical Ventilation</title>
        <description>Duration of mechanical ventilation use in days. Multiple mechanical ventilation durations are summed up.</description>
        <time_frame>Measured from Day 0 through Day 28</time_frame>
        <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza.</population>
        <group_list>
          <group group_id="O1">
            <title>Plasma and Standard Care</title>
            <description>Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies in addition to standard care.
Anti-Influenza Immune Plasma: 2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Participants will receive standard care.
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Mechanical Ventilation</title>
          <description>Duration of mechanical ventilation use in days. Multiple mechanical ventilation durations are summed up.</description>
          <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="6"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disposition Following Initial Hospitalization</title>
        <description>Disposition following initial hospitalization was categorized as follows: &quot;released home - home health care not required&quot;, &quot; released home with home health care&quot;, &quot;transferred to long-term care facility&quot;, &quot;hospitalization ongoing at Day 28&quot;, &quot;deceased&quot;.</description>
        <time_frame>Measured from Day 0 through Day 28</time_frame>
        <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza.</population>
        <group_list>
          <group group_id="O1">
            <title>Plasma and Standard Care</title>
            <description>Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies in addition to standard care.
Anti-Influenza Immune Plasma: 2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Participants will receive standard care.
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
        </group_list>
        <measure>
          <title>Disposition Following Initial Hospitalization</title>
          <description>Disposition following initial hospitalization was categorized as follows: &quot;released home - home health care not required&quot;, &quot; released home with home health care&quot;, &quot;transferred to long-term care facility&quot;, &quot;hospitalization ongoing at Day 28&quot;, &quot;deceased&quot;.</description>
          <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>released home - home health care not required</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>released home with home health care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>transferred to long-term care facility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hospitalization ongoing at Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>deceased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Viral Shedding &lt; Lower Limit of Quantification (LLOQ) in Nasal Swabs</title>
        <description>Duration of viral shedding &lt; lower limit of quantification (LLOQ) in nasal swabs (restricted to participants with viral shedding &gt;= LLOQ in nasal swabs at Day 0)</description>
        <time_frame>Measured from Day 0 through Day 28</time_frame>
        <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza. This subset was further restricted to those participants with viral shedding &gt;= LLOQ in nasal swabs at Day 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Plasma and Standard Care</title>
            <description>Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies in addition to standard care.
Anti-Influenza Immune Plasma: 2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Participants will receive standard care.
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Viral Shedding &lt; Lower Limit of Quantification (LLOQ) in Nasal Swabs</title>
          <description>Duration of viral shedding &lt; lower limit of quantification (LLOQ) in nasal swabs (restricted to participants with viral shedding &gt;= LLOQ in nasal swabs at Day 0)</description>
          <population>The population analyzed is the Primary Efficacy Population (PEP), defined as the subset of randomized participants who tested positive for influenza. This subset was further restricted to those participants with viral shedding &gt;= LLOQ in nasal swabs at Day 0.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1">Upper quartile is not available because fewer than 75% of the analyzed participants had viral shedding &lt; LLOQ in nasal swabs. Lower quartile and median were estimated from Kaplan-Meier analysis.</measurement>
                    <measurement group_id="O2" value="1" lower_limit="1">Upper quartile is not available because fewer than 75% of the analyzed participants had viral shedding &lt; LLOQ in nasal swabs. Lower quartile and median were estimated from Kaplan-Meier analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence and Week of Gestation of Delivery of a Live Pre-term Infant for Pregnant Women</title>
        <description>Incidence and week of gestation of delivery of a live pre-term infant for pregnant female participants</description>
        <time_frame>Measured through to Day 28</time_frame>
        <population>Measure was not analyzed since there was only one pregnant participant. No aggregate results were available for posting, and the individual participant-level data were not posted due to being potentially identifiable.</population>
        <group_list>
          <group group_id="O1">
            <title>Plasma and Standard Care</title>
            <description>Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies in addition to standard care.
Anti-Influenza Immune Plasma: 2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Participants will receive standard care.
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence and Week of Gestation of Delivery of a Live Pre-term Infant for Pregnant Women</title>
          <description>Incidence and week of gestation of delivery of a live pre-term infant for pregnant female participants</description>
          <population>Measure was not analyzed since there was only one pregnant participant. No aggregate results were available for posting, and the individual participant-level data were not posted due to being potentially identifiable.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence and Duration of Pre-term Labor (Defined as Labor Occurring &lt; 36 Weeks) for Pregnant Women</title>
        <description>Incidence and duration of pre-term labor (defined as labor occurring &lt; 36 weeks) for pregnant female participants</description>
        <time_frame>Measured through Day 28</time_frame>
        <population>Measure was not analyzed since there was only one pregnant participant. No aggregate results were available for posting, and the individual participant-level data were not posted due to being potentially identifiable.</population>
        <group_list>
          <group group_id="O1">
            <title>Plasma and Standard Care</title>
            <description>Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies in addition to standard care.
Anti-Influenza Immune Plasma: 2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Participants will receive standard care.
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence and Duration of Pre-term Labor (Defined as Labor Occurring &lt; 36 Weeks) for Pregnant Women</title>
          <description>Incidence and duration of pre-term labor (defined as labor occurring &lt; 36 weeks) for pregnant female participants</description>
          <population>Measure was not analyzed since there was only one pregnant participant. No aggregate results were available for posting, and the individual participant-level data were not posted due to being potentially identifiable.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Spontaneous Abortion or Stillborn Fetus for Pregnant Women</title>
        <description>Incidence of spontaneous abortion or stillborn fetus for pregnant female participants</description>
        <time_frame>Measured from Day 0 through Day 28</time_frame>
        <population>Measure was not analyzed since there was only one pregnant participant. No aggregate results were available for posting, and the individual participant-level data were not posted due to being potentially identifiable.</population>
        <group_list>
          <group group_id="O1">
            <title>Plasma and Standard Care</title>
            <description>Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies in addition to standard care.
Anti-Influenza Immune Plasma: 2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Participants will receive standard care.
Standard Care: Standard care for hospitalized people with influenza</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Spontaneous Abortion or Stillborn Fetus for Pregnant Women</title>
          <description>Incidence of spontaneous abortion or stillborn fetus for pregnant female participants</description>
          <population>Measure was not analyzed since there was only one pregnant participant. No aggregate results were available for posting, and the individual participant-level data were not posted due to being potentially identifiable.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected throughout the conduct of the study; from Day 0 to Day 28</time_frame>
      <desc>Adverse events were assessed by treatment received (as opposed to randomized treatment).The Participant Flow is presented by randomized treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Plasma and Standard Care</title>
          <description>Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies in addition to standard care.
Anti-Influenza Immune Plasma: 2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
Standard Care: Standard care for hospitalized people with influenza</description>
        </group>
        <group group_id="E2">
          <title>Standard Care</title>
          <description>Participants will receive standard care.
Standard Care: Standard care for hospitalized people with influenza</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Abdominal compartment syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase MB increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pulmonary thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Endotracheal intubation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Thoracostomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Blood sodium increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Alkalosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Beigel, M.D.</name_or_title>
      <organization>Leidos Biomedical Research, Inc. is support to the National Institute of Allergy and Infectious Diseases (NIAID)</organization>
      <phone>301-451-9881</phone>
      <email>jbeigel@niaid.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

